- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.12.24 | Lytix Biopharma AS - New share capital registered | 2 | Cision News | ||
| 17.12.24 | Lytix Biopharma AS: Key information relating to potential subsequent offering | 1 | Cision News | ||
| 17.12.24 | Lytix Biopharma AS - Mandatory notification of trade by Primary Insiders and close associates | 1 | Cision News | ||
| 17.12.24 | Lytix Biopharma AS: Private placement and retail offer via PrimaryBid successfully completed | 1 | Cision News | ||
| 16.12.24 | Lytix Biopharma AS: Contemplated private placement and retail offer via PrimaryBid | 3 | Cision News | ||
| 16.12.24 | Lytix Biopharma AS: Lytix Biopharma - Lytix launches Retail Offering via Primary Bid and Nordnet, in parallel with private placement | 1 | Oslo Børs | ||
| 21.11.24 | LYTIX BIOPHARMA AS: Lytix Biopharma - Licensing partner Verrica Pharmaceuticals announces pricing of underwritten public offering, raising approximately USD 42 million upon completion | 4 | Cision News | ||
| 19.11.24 | LYTIX BIOPHARMA AS: Lytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization | 1 | Cision News | ||
| LYTIX BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 12.11.24 | LYTIX BIOPHARMA AS: Lytix Biopharma: Invitation to Q3 2024 Results Presentation | 1 | Cision News | ||
| 06.11.24 | Lytix Biopharma AS: First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo - promising use of Lytix cancer treatment in patients with early-stage melanoma | - | Oslo Børs | ||
| 05.11.24 | LYTIX BIOPHARMA AS: Lytix Biopharma - Update from licensing partner Verrica Pharmaceuticals | 11 | Cision News | ||
| 01.11.24 | Lytix Biopharma AS: Financial calendar | 1 | Oslo Børs | ||
| 24.10.24 | LYTIX BIOPHARMA AS: Lytix Biopharma Highlights Positive Data on LTX-315 in Collaboration with Verrica Pharmaceuticals at 2024 Fall Clinical Dermatology Conference | 2 | Cision News | ||
| 29.08.24 | LYTIX BIOPHARMA AS: Lytix Biopharma Q2 and H1 2024 results: Significant clinical advancements take Lytix Biopharma closer to commercialization | 3 | Cision News | ||
| 23.08.24 | LYTIX BIOPHARMA AS: Lytix Biopharma: Invitation to Q2 2024 Results Presentation | 1 | Cision News | ||
| 14.08.24 | LYTIX BIOPHARMA AS: PhII preliminary results from skin cancer clinical trial show an 86%overall reduction of tumor size, complete clearance in 51%of the patients and the potential to be utilized as a first-line therapy | 3 | Cision News | ||
| 06.08.24 | LYTIX BIOPHARMA AS: Lytix Biopharma: Lytix's licensing partner, Verrica Pharmaceuticals, to release preliminary topline results from their Phase II trial of LTX-315 for the treatment of basal cell carcinoma on August 14 | 4 | Cision News | ||
| 06.08.24 | Lytix Biopharma AS: Lytix' lisensieringspartner Verrica Pharmaceuticals publiserer foreløpige hovedresultater fra del 2 av deres fase II-studie av LTX-315 i hudkreftsykdommen basalcellekarsinom onsdag 14. august 2024 | 2 | Oslo Børs |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 45,300 | +1,48 % | Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions | Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly versus... ► Artikel lesen | |
| JANUX THERAPEUTICS | 53,54 | +1,98 % | Janux Therapeutics CEO David Campbell verkauft Aktien im Wert von 1,4 Millionen US-Dollar | ||
| TEMPUS AI | 33,760 | 0,00 % | Cathie Woods ARK kauft AMD und TEMPUS AI, verkauft ARCHER AVIATION | ||
| QUANTUM-SI | 2,690 | 0,00 % | Pre-market Movers: Intrusion, SES AI, Solid Power, Quantum-Si, Rail Vision | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green Intrusion Inc. (INTZ) is up over 380% at $2.16.
SES... ► Artikel lesen | |
| HUMACYTE | 5,050 | 0,00 % | Humacyte (NASDAQ:HUMA) Shares Up 6% - Here's What Happened | ||
| RECURSION PHARMACEUTICALS | 6,765 | 0,00 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 76,96 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome | Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those... ► Artikel lesen | |
| IMMUNOVANT | 24,770 | +3,73 % | Immunovant stock hits 52-week low at $24.61 amid market challenges | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 54,15 | 0,00 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody sonelokimab in patients with active psoriatic arthritis | MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
Two trials for active psoriatic arthritis (PsA) with one focusing... ► Artikel lesen | |
| KEROS THERAPEUTICS | 15,830 | 0,00 % | Keros Therapeutics-Aktie erreicht 52-Wochen-Tief bei 15,67 US-Dollar | ||
| OLEMA PHARMACEUTICALS | 5,830 | +3,92 % | Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium | Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability in patients with... ► Artikel lesen | |
| THIRD HARMONIC BIO | 10,290 | -0,87 % | Third Harmonic Bio Announces Third Quarter 2024 Financial Results | THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $296.1 million as of September 30, 2024 SAN FRANCISCO... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 55,38 | 0,00 % | Tarsus Pharmaceuticals-Aktie erreicht 52-Wochen-Hoch von 56,84 US-Dollar | ||
| ARS PHARMACEUTICALS | 10,550 | 0,00 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates | Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive... ► Artikel lesen | |
| ARCELLX | 76,86 | -1,90 % | Arcellx Stock Earns 82 Relative Strength Rating |
LYTIX BIOPHARMA AS gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,482 Euro und damit +3,43 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LYTIX BIOPHARMA AS finden Sie auf Wallstreet Online.
